

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017

<https://marketpublishers.com/r/C58E4D86947EN.html>

Date: October 2017

Pages: 35

Price: US\$ 3,500.00 (Single User License)

ID: C58E4D86947EN

Abstracts

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017

SUMMARY

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report C-C Chemokine Receptor Type 1 - Pipeline Review, H2 2017, outlays comprehensive information on the C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - C-C chemokine receptor type 1 is a protein encoded by the CCR1 gene. CCR1 binds to multiple chemokines (including CCL4, CCL5, CCL6, CCL14, CCL15, CCL16 and CCL23). This receptor is found on peripheral blood lymphocytes and monocytes. This chemokine receptor is restricted to memory T-cells within the lymphocyte pool. This receptor is also designated cluster of differentiation marker CD191. The molecules

developed by companies in Phase II and Preclinical stages are 1 and 6 respectively. Report covers products from therapy areas Immunology, Oncology and Infectious Disease which include indications Rheumatoid Arthritis, Autoimmune Disorders, Blood Cancer, Bone Metastasis, Breast Cancer, Lupus Nephritis and Systemic Candidiasis.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)

The report reviews C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics and enlists all

their major and minor projects

The report assesses C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1)

development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Overview

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

ChemoCentryx Inc

Ligand Pharmaceuticals Inc

Novartis AG

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Drug Profiles

BL-5923 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-354 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-9588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CCR1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CCR1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CCR1,4,5,6 and CXCR2,7 for Oncology and Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Dormant Products

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Discontinued Products

C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Product Development Milestones

Featured News & Press Releases

Apr 18, 2016: ChemoCentryx Announces Immuno-Oncology Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Nov 04, 2015: ChemoCentryx presents CCX-9588 preclinical results at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Jun 08, 2012: ChemoCentryx Announces Peer-Reviewed Publication Of Positive Phase II Clinical Data With CCX354 In Patients With Rheumatoid Arthritis

Nov 08, 2011: ChemoCentryx Reports Clinical Efficacy For CCX354 In Phase II Study In Patients With Rheumatoid Arthritis

Nov 09, 2010: ChemoCentryx Reports Favorable Phase I Results For CCX354 In Rheumatoid Arthritis At Annual American College Of Rheumatology Meeting

Jun 17, 2010: ChemoCentryx Reports Positive Phase I Study Results For CCX354

Dec 16, 2009: ChemoCentryx Initiates Phase 2 Clinical Trial Of CCX354 For The Treatment Of Rheumatoid Arthritis

May 13, 2008: ChemoCentryx Initiates Clinical Trial Of CCX354 For The Treatment Of Inflammatory Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by ChemoCentryx Inc, H2 2017

Pipeline by Ligand Pharmaceuticals Inc, H2 2017

Pipeline by Novartis AG, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

COMPANIES MENTIONED

Bristol-Myers Squibb Co

ChemoCentryx Inc

Ligand Pharmaceuticals Inc

Novartis AG

I would like to order

Product name: C-C Chemokine Receptor Type 1 (HM145 or LD78 Receptor or Macrophage Inflammatory Protein 1 Alpha Receptor or RANTES R or CD191 or CCR1) - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/C58E4D86947EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C58E4D86947EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970